Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 2
R&D Momentum
66/100
Pipeline Velocity
37/100
Trial Completion Rate
94/100
Pipeline Concentration
38/100
Pipeline Freshness
39/100
Strategic Signals
Activity
Last 14 days
Post-ICU Syndrome: Exploring the Role of Social Determinants on Trajectories and Outcomes
Fibromyalgia and Functional Impact: the Complementary Role of Neural Mobilization.
A Randomized, Double-blind Feasibility Study of a Subject-independent Classifier-based EEG Neurofeedback in Women With Depressive Symptoms
Incremental Dead Space Versus Capping Trial to Predict the Post-Decannulation Respiratory Status in Tracheostomized Critically Ill Patients: A Physiological Randomized Crossover Study
Impact of EEG-guided Sevoflurane Titration on Opioid Consumption and Emergency Quality in Pediatric Patients Undergoing Surgery Without Regional Anesthesia
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)